CRESCENT BIOPHARMA, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

CRESCENT BIOPHARMA, INC. reported Cash And Cash Equivalents At Carrying Value of $213.19 million for the year ending 2025.

  • CRESCENT BIOPHARMA, INC. showed an increase of +513.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 15 years of available data (2011 to 2025), CRESCENT BIOPHARMA, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 656.7%.
  • Historical annual values: Fiscal year 2025: $213.19 million | Fiscal year 2024: $34.77 million | Fiscal year 2023: $41.79 million | Fiscal year 2022: $47.87 million | Fiscal year 2021: $90.25 million | Fiscal year 2020: $137.04 million | Fiscal year 2019: $158.20 million | Fiscal year 2018: $209.92 million | Fiscal year 2017: $123.92 million | Fiscal year 2016: $40.04 million | Fiscal year 2015: $46.80 million | Fiscal year 2014: $55.20 million | Fiscal year 2013: $2.31 million | Fiscal year 2012: $17.37 million | Fiscal year 2011: $28.17 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: